Weight ManagementJuly 28, 2026·4 min read
By the CIRRUS Editorial Team — how we write and source this
The muscle-loss problem with GLP-1 drugs — and why resistance training isn't optional
Rapid weight loss on semaglutide or tirzepatide comes disproportionately from lean mass unless you actively train against it.
Body composition studies on GLP-1 users have found that roughly a quarter to 40% of total weight lost can be lean mass rather than fat, depending on baseline activity level and protein intake — a meaningfully worse ratio than weight lost through resistance-trained, high-protein dieting alone. For older adults already at risk of sarcopenia, that lean-mass loss carries real functional consequences: grip strength, gait speed, and fall risk.
The fix isn't complicated but it is effortful: two to three resistance-training sessions a week and a protein target in the range clinicians increasingly recommend for GLP-1 users — often cited around 1.0 to 1.2 grams per kilogram of body weight daily, higher than general population guidance. Appetite suppression from the drug can make hitting that protein target harder, which is its own coaching problem worth raising with a prescriber or dietitian.
For patients managing a respiratory or cardiac condition alongside GLP-1 therapy, preserving muscle mass has a second benefit beyond mobility: respiratory muscle strength (diaphragm, intercostals) is skeletal muscle too, and unmanaged lean-mass loss during rapid weight loss can measurably affect breathing mechanics.
This article is general health information, not medical advice, and doesn’t replace evaluation by your own physician. Talk to a doctor about anything specific to your own diagnosis or treatment.